Last reviewed · How we verify
Foam sclerotherapy
Foam sclerotherapy involves injecting a sclerosing agent in foam form into abnormal veins to cause inflammation and fibrosis, leading to vein closure and reabsorption.
Foam sclerotherapy involves injecting a sclerosing agent in foam form into abnormal veins to cause inflammation and fibrosis, leading to vein closure and reabsorption. Used for Varicose veins, Venous insufficiency, Spider veins and telangiectasia.
At a glance
| Generic name | Foam sclerotherapy |
|---|---|
| Sponsor | Imperial College London |
| Drug class | Sclerosing agent |
| Modality | Small molecule |
| Therapeutic area | Vascular/Dermatology |
| Phase | FDA-approved |
Mechanism of action
The foam formulation increases the surface area contact between the sclerosing agent and the vein endothelium, enhancing efficacy compared to liquid sclerotherapy. The sclerosant damages the vein wall, triggering an inflammatory response that results in fibrosis and permanent closure of the targeted vessel. This allows blood flow to be redirected through healthy veins.
Approved indications
- Varicose veins
- Venous insufficiency
- Spider veins and telangiectasia
Common side effects
- Thrombophlebitis
- Skin necrosis
- Hyperpigmentation
- Matting (new telangiectasia)
- Allergic reaction
Key clinical trials
- Comparison of Radiofrequency Ablation With Concomitant or Staged Treatment for Tributary Varicose Veins (NA)
- Prolonged Compression Following Foam Sclerotherapy (NA)
- Caprini Score in Venous Surgery: a Prospective Cohort Study
- A Prospective Observational Study of Foam Sclerotherapy .
- Polidocanol Foam With or Without Transdermal Laser for Varicose Veins: Randomized Clinical Trial (NA)
- Efficacy of the SALFOAM 3% Method Compared to the Conventional Polidocanol Foam Method (Tessari Method) for Treating Lower Limb Varicose Veins (NA)
- Efficacy and Safety of Endovenous Ablation for Relief of Knee Pain in Elderly Patients With Lower Extremity Varicose Veins: A Prospective Observational Study
- Embolization Strategies for Pelvic Venous Disorders: Foam + Glue vs Foam + Coils (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foam sclerotherapy CI brief — competitive landscape report
- Foam sclerotherapy updates RSS · CI watch RSS
- Imperial College London portfolio CI